Analysis of PTEN, estrogen receptor α and progesterone receptor expression in endometrial hyperplasia using tissue microarray

Polish Journal of Pathology

Volumn 62, Issue 3, 2011, Pages 133-138

  Pieczyńska, Beata ^a   Wojtylak, Szymon ^a   Zawrocki, Anton ^a   Biernat, Wojciech ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Endometrial carcinogenesis; Estrogen receptor; Immunohistochemistry; Progesterone receptor; PTEN

Indexed keywords

ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA, HUMAN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGESTERONE RECEPTOR; PTEN PROTEIN, HUMAN;

ARTICLE; CELL PROLIFERATION; ENDOMETRIUM; ENDOMETRIUM HYPERPLASIA; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; TISSUE MICROARRAY;

CELL PROLIFERATION; ENDOMETRIAL HYPERPLASIA; ENDOMETRIUM; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PTEN PHOSPHOHYDROLASE; RECEPTORS, PROGESTERONE; TISSUE ARRAY ANALYSIS;

EID: 81355154337     PISSN: 12339687     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Doll A, Abal M, Rigau M, et al. Novel molecular profiles of endometrial cancer new light through old window. J Steroid Biochem Mol Biol 2008; 108: 221-229.
2. Prat J, Gallardo A, Cuatrecasas M, et al. Endometrial carcionoma: pathology and genetics. Pathology 2007; 39: 72-87.
3. Samarnthai N, Hall K, Yeh IT. Molecular profiling of endometrial malignancies. Obstet Gynecol Int 2010; 2010: 162363.
4. Baak JP, Van Diermen B, Steinbakk A. Lack of PTEN expression in endometrial intraepithelial neoplasia is correlated with cancer progression. Hum Pathol 2005; 36: 555-561.
5. Mutter GL, Lin MC, Fitzgerald JT. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 2000; 92: 924-930.
6. Bergeron C, Ferenczy A, Toft DO, et al. Immunocytochemical study of progesterone receptors in hyperplastic and neoplastic endometrial tissues. Cancer Res 1988; 48: 6132-6136.
7. Cai HB, Zhou YF, Wang BC, et al. Expression of estrogen re-ceptors α and β protein in endometrial carcionoma. Cancer Ther 2008; 6: 907-912.
8. Chakraborty S, Khurana N, Sharma JB, et al. Endometrial hormone receptors in women with dysfunctional uterine bleeding. Arch Gynecol Obstet 2005; 272: 17-22.
9. Hu K, Zhong G, He F. Expression of estrogen receptors ERα and ERβ in endometrial hyperplasia and adenocarcionoma. Int J Gynecol Cancer 2005; 15: 537-541.
10. Masuzawa H, Badokhon NH, Nakayama K, et al. Failure of down regulation of estrogen receptors and progesterone receptors after medroxyprogesterone acetate administration for endometrial hyperplasia. Cancer 1994; 74: 2321-2328.
11. Nunobiki O, Taniguchi E, Ishii A, et al. Significance of hormone receptor status and tumor vessels in normal, hyperplastic and neoplastic endometrium. Pathol Int 2003; 53: 846-852.
12. Nyholm HC, Nielsen AL, Lyndrup J, et al. Biochemical and im-munohistochemical estrogen and progesterone receptors in adenomatous hyperplasia and endometrial carcinoma: correlation with stage and other clinicopathologic features. Am J Obstet Gynecol 1992; 167: 1334-1342.
13. Mazur MT, Kurman RJ. Diagnosis of endometria biopsies and curettings. Springer-Verlag, New York, Berlin, Heidelberg, London, Paris, Tokyo, Hong Kong, Barcelona, Budapest 1995.
14. Tavassoli FA, Devilee P. World Health Organization Classification of Tumours. Pathology & Genetics. Tumours of the Breast and Female Genital Organs.
15. Cirpan T, Terek MC, Mgoyi L, et al. Immunohistochemical evaluation of PTEN protein in patients with endometrial intraepithelial neoplasia compared to endometrial carcinoma and proliferative phase endometrium. Eur J Gynecol Oncol 2006; 27: 389-392.
16. Kapucuoglu N, Aktepe F, Kaya H, et al. Immunohistochem ical expression of PTEN in normal, hyperplastic and maligna t endometrium and its correlation with hormone receptors, bcl-2, bax, and apoptotic index. Pathol Res Pract 2007; 203: 153-162.
17. Kimura F, Watanabe J, Hata H, et al. PTEN immunohisto chemicalexpression is suppressed in G1 endometrioid adenocarcinoma of uterine corpus. J Cancer Res Clin Oncol 2004; 130: 161-168.
18. Allison KH, Tenpenny E, Reed SD, et al. Immunohistochemical markers in endometrial hyperplasia: Is there a panel with promise? Appl Immunohistochem Mol Morphol 2008; 16: 329-343.
19. BńA, Michalak J, Sporny S. Immunoexpression and clinical significance of the PTEN and MLH1 proteins in endometrial carcinomas. Pol J Pathol 2010; 4: 185-191.
20. Sarmadi S, Izadi-Mood N, Sotoudeh K, et al. Altered PTEN expression; a diagnostic marker for differentiating normal, hyper-plastic and neoplastic endometrium. Diag Pathol 2009; 4: 41.
21. Mutter GL, Ince TA, Baak JP, et al. Molecular identification of latent precancers in histologically normal endometrium. Cancer Res 2001; 61: 4311-4314.
22. Lacey JM, Mutter GL, Ronnett BM, et al. PTEN expression in endometrial biopsies as a marker of progression to endometrial carcinoma. Cancer Res 2008; 68: 6014-6020.
23. Pallares J, Bussaglia E, Martinez-Guitarte JL, et al. Immuno histochemical analysis of PTEN in endometrial carcinoma: a tissue microarray study with a comparison of four commercial antibodies in correlation with molecular abnormalities. Mod Pathol 2005; 18: 719-727.
24. Bircan S, Ensari A, Ozturk S, et al. Immunohistochemical analysis of c-myc, c-jun, and estrogen receptor in normal, hyperplastic and neoplastic endometrium. Pathol Oncol Res 2005; 11: 32-39.
25. Uchikawa J, Shiozawa T, Shih HC, et al. Expression of steroid receptor coactivators and corepressors in human endometrial hyperplasia and carcinoma with relevance to steroid receptors and Ki-67 expression. Cancer 2003; 98: 2207-2213.